ArdelyxARDX
About: Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Employees: 267
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
24% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 33
4% more funds holding
Funds holding: 186 [Q1] → 194 (+8) [Q2]
8% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 61
2% more capital invested
Capital invested by funds: $1.05B [Q1] → $1.07B (+$17.4M) [Q2]
0.24% less ownership
Funds ownership: 61.69% [Q1] → 61.45% (-0.24%) [Q2]
13% less call options, than puts
Call options by funds: $18M | Put options by funds: $20.6M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Ed Arce 56% 1-year accuracy 61 / 109 met price target | 93%upside $11 | Buy Maintained | 5 Aug 2024 |
Citigroup Yigal Nochomovitz 57% 1-year accuracy 21 / 37 met price target | 110%upside $12 | Buy Maintained | 2 Aug 2024 |
Wedbush Laura Chico 59% 1-year accuracy 36 / 61 met price target | 93%upside $11 | Outperform Reiterated | 2 Aug 2024 |
Financial journalist opinion
Based on 193 articles about ARDX published over the past 30 days
